Competitor Analysis: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

Publisher: La Merie Publishing
Pages: 71
Format: PDF
Product Line:
Competitor Analysis
Product Code: LMCA0037
Release Date: August of 2014

350.00 €
Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product


Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

The Competitive Intelligence Report Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists as of August 2014 provides a competitor analysis in the development pipeline of novel GLP-1 analogs and GLP-1 receptor agonists and co-agonists for treatment of diabetes and obesity.

In the year 2013, the marketed daily and weekly GLP-1 agonists achieved combined sales of US$ 3,231 mln representing 6.3% of the total diabetes care market. The leading GLP-1 analog Victoza held 69% of the GLP-1 market and is further expanding its predominance in the first half of 2014 with a 72% share of the GLP-1 market which grew to 6.9% of the total diabetes care market.
The increasingly attractive GLP-1 market provides an opportunity of application of new technologies to prolong the half-life of GLP-1 analogs as well as finding co-agonists of GLP-1 receptor with additional receptors, such as insulin, glucagon, GIP, gastrin or GLP-1. In addition, expansion of indications for GLP-1 analogs will contribute to further expand the GLP-1 market.

The report provides a compilation of current active projects in research and development of novel GLP-1 analogs and GLP-1 receptor agonists as well as co-agonists. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

Table of Contents

1. Selective GLP-1 Analogs for Metabolic Diseases

  • 2013 Sales of GLP-1 Analogs
  • Short-Acting Injectable GLP-1 Analogs
  • Long-Acting Injectable GLP-1 Analogs
  • Very Long-Acting Injectable GLP-1 Analogs
  • Oral Peptide-Based GLP-1 Analogs
  • Other Non-Injectable Peptide-Based GLP-1 Analogs
  • Oral Small Molecule GLP-1 Receptor Agonists

2. Selective GLP-1 Analogs for Non-Metabolic Diseases

3. Dual Target GLP-1 Analogs

  • GLP-1 and Insulin
  • GLP-1 and Glucagon
  • GLP-1 and GIP
  • GLP-1 and Gastrin/CCKB
  • GLP-1 and GLP-2

4. Corporate GLP-1 Receptor Agonist R&D Pipelines

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

Companies mentioned in the report

Addex Therapeutics
Aegis Therapeutics
Arisaph Pharmaceuticals
AstraZeneca (MedImmune)
Boehringer Ingelheim
Dong-A Pharmaceutical (Dong-A Socio Holding)
Eli Lilly
Flamel Technologies
Foresee Pharmaceuticals
Hanmi Pharmaceuticals
Heptares Therapeutics
Il-Dong Pharma
Intarcia Therapeutics
Jiangsu HengRui Medicine Co
LG Life Science
Midasol Therapeutics
Novo Nordisk
OJSC PharmSynthez
OPKO Health
Oramed Pharmaceuticals
Proxima Concepts
Spitfire Pharma
TransTech Pharma
Uni-Bio Science
Xenetic Biosciences
Zealand Pharma

The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up